Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition

被引：16
|
作者：
Musunuru, Kiran [1 ]
机构：
[1] Univ Penn, Cardiovasc Inst, Dept Med, Dept Genet,Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 | 2021年 / 72卷
关键词：
cholesterol; coronary artery disease; genetics; inflammation; lipoproteins; triglycerides; OF-FUNCTION MUTATIONS; C-REACTIVE PROTEIN; DENSITY-LIPOPROTEIN CHOLESTEROL; TRIGLYCERIDE TRANSFER PROTEIN; HIGH-RISK; CARDIOVASCULAR-DISEASE; HEART-DISEASE; DOUBLE-BLIND; TARGETING APOLIPOPROTEIN(A); MENDELIAN RANDOMIZATION;
D O I：
10.1146/annurev-med-080819-044918
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Statins, ezetimibe, and PCSK9 inhibitors are currently the standard of care for the prevention and treatment of coronary artery disease. Despite their widespread use, coronary artery disease remains the leading cause of death worldwide, a fact that pleads for the development of new protective therapies. In no small part due to advances in the field of human genetics, many new therapies targeting various lipid traits or inflammation have recently received approval from regulatory agencies such as the US Food and Drug Administration or fared favorably in clinical trials. This wave of new therapies promises to transform the care of patients at risk for life-threatening coronary events.
引用
收藏
页码：447 / 458
页数：12
相关论文
共 50 条
  • [1] Effect of PCSK9 inhibition on platelet reactivity in coronary artery disease patients
    Galli, Lukas
    Ondracek, Anna
    Seidl, Veronika
    Hofbauer, Thomas
    Zedan, Yasmin
    Schrutka, Lore
    Krychtiuk, Konstantin
    Lang, Irene M.
    Speidl, Walter
    Distelmaier, Klaus
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2019, 131 : 372 - 373
  • [2] PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease
    Gebauer, Katrin
    Reinecke, Holger
    [J]. VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2018, 47 (03) : 165 - 176
  • [3] FAMILIAL HYPERCHOLESTEREMIA: WHEN STATINS, EZETIMIBE & PCSK9 INHIBITORS ARE NOT ENOUGH
    Verma, Isha
    Fernandez, Antonio
    Thompson, Paul
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 2439 - 2439
  • [4] COST-EFFECTIVENESS OF STATINS, EZETIMIBE AND PCSK9 INHIBITOR FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE
    Xiang, Y.
    Du, H.
    Gan, L.
    Li, S.
    Hu, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S408 - S408
  • [5] Intolerance to statins and response to PCSK9 inhibition with AMG 145
    Sullivan, D.
    Civeira, F.
    Watts, G. F.
    Shou, M. B.
    Tikkanen, M. J.
    Simons, L. A.
    Masana, L.
    Kim, J. B.
    Xue, A.
    Stein, E. A.
    [J]. EUROPEAN HEART JOURNAL, 2013, 34 : 135 - 135
  • [6] PROGNOSTIC VALUE OF PCSK9 AND LP(A) IN STABLE CORONARY ARTERY DISEASE
    Acena, Alvaro
    Alvarez de Toledo, Cristina
    Maria Pello, Ana
    Tarin, Nieves
    Cristobal, Carmen
    Huelmos, Ana
    Gutierrez Landaluce, Carlos
    Lopez Castillo, Marta
    Lorenzo, Oscar
    Martin Mariscal, Maria Luisa
    Martinez Milla, Juan
    Gonzalez Lorenzo, Oscar
    Hernandez Gonzalez, Ignacio
    Tunon Fernandez, Jose
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 100 - 100
  • [7] Thyroid function and PCSK9 in euthyroid subjects with coronary artery disease
    Li, Sha
    Xu, Rui-Xia
    Guo, Yuan-Lin
    Zhang, Yan
    Zhu, Cheng-Gang
    Sun, Jing
    Li, Jian-Jun
    [J]. CLINICAL LIPIDOLOGY, 2015, 10 (03) : 235 - 242
  • [8] Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke
    Marchis, Gian Marco De
    Dittrich, Tolga D.
    Malik, Rainer
    V. Zietz, Annaelle
    Kriemler, Lilian F.
    Ference, Brian A.
    Dichgans, Martin
    Georgakis, Marios K.
    [J]. ATHEROSCLEROSIS, 2022, 361 : 41 - 46
  • [9] NO ASSOCIATION BETWEEN CHANGES IN LIPID PARAMETERS AND TOTAL PCSK9 IN CORONARY ARTERY DISEASE PATIENTS TREATED WITH PCSK9 INHIBITORS
    Ugovsek, S.
    Likozar, A. Rehberger
    Sebestjen, M.
    [J]. ATHEROSCLEROSIS, 2023, 379 : S173 - S173
  • [10] A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes
    Khan, Safi U.
    Talluri, Swapna
    Riaz, Haris
    Rahman, Hammad
    Nasir, Fahad
    Bin Riaz, Irbaz
    Sattur, Sudhakar
    Ahmed, Haitham
    Kaluski, Edo
    Krasuski, Richard
    [J]. EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2018, 25 (08) : 844 - 853
12345